Description

Lyperlipidemia, a common disease in present society, has become one of the three health killers with an increasing incidence. Lyperlipidemia can lead to atherosclerosis, coronary heart disease, stroke, myocardial infarction, hemiplegia and so on. Besides, a high level of blood fat will induce such severe diseases as hypertension, hyperglycemia, fatty liver, pancreatitis and fundus hemorrhage which not only cause serious damage but also influence patients’ life quality.

View Full Report at:http://www.marketresearchreports.biz/analysis/294371

With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .

Simvastatin, a new generation of HMG-COA reductase inhibitor produced by restructuring lovastatin, was introduced into China by MSD (China) in 1995. Domestic simvastatin was developed by Sichuan Industrial Institute of Antibiotics. Simvastatin develops fast after entering China, sales value being CNY 104 million in 2005 and CNY 197 million in 2010. However, later, its sales began to drop to CNY 156 million in 2014. Hangzhou MSD Pharmaceutical Co., Ltd, Merck Sharp & Dohme (UK), Guangzhou Nanxin Pharmaceutical Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Shandong Lukang Pharmaceutical Co., Ltd occupy the majority of market, among which Hangzhou MSD Pharmaceutical Co., Ltd has the largest market share of 39% for sales value in 2014.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/294371

The sales value of simvastatin will stay at a certain level in a given period despite a downtrend in recent years.




Readers can get at least the following information from this report:

market size of simvastatin in China
price of simvastatin in China
market outlook of simvastatin in China

The author suggests the following groups of people purchase this report:

manufacturers of lipid-lowering drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service


Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]